 John. R. Edwardson on Aug 17th, 2018 // No Comments
Zacks Investment Research cut shares of Aeglea Bio Therapeutics (NASDAQ:AGLE) from a hold rating to a sell rating in a research report report published on Tuesday morning.
According to Zacks, "Aeglea BioTherapeutics, Inc. is a biotechnology company which is engaged in developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. Its portfolio of products consists of AEB1102, AEB3103, AEB2109 and AEB4104 which are in different clinical trial phase. Aeglea BioTherapeutics, Inc. is based in Austin, Texas. " Get Aeglea Bio Therapeutics alerts:
Several other equities analysts also recently commented on AGLE. Evercore ISI started coverage on shares of Aeglea Bio Therapeutics in a report on Tuesday, April 24th. They set an outperform rating and a $37.00 price target on the stock. ValuEngine upgraded shares of Aeglea Bio Therapeutics from a sell rating to a hold rating in a report on Wednesday, May 2nd. Finally, BMO Capital Markets started coverage on shares of Aeglea Bio Therapeutics in a report on Thursday, June 14th. They set an outperform rating and a $21.00 price target on the stock. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Aeglea Bio Therapeutics presently has an average rating of Buy and a consensus target price of $22.50. Shares of NASDAQ:AGLE opened at $9.22 on Tuesday. The stock has a market cap of $208.51 million, a P/E ratio of -5.12 and a beta of -0.44. Aeglea Bio Therapeutics has a 12 month low of $2.81 and a 12 month high of $12.00.
Aeglea Bio Therapeutics (NASDAQ:AGLE) last issued its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.10). The firm had revenue of $2.38 million for the quarter. Aeglea Bio Therapeutics had a negative net margin of 480.92% and a negative return on equity of 57.15%. equities analysts predict that Aeglea Bio Therapeutics will post -1.67 earnings per share for the current fiscal year.
A number of large investors have recently modified their holdings of the stock. Nantahala Capital Management LLC grew its holdings in Aeglea Bio Therapeutics by 20.0% during the 2nd quarter. Nantahala Capital Management LLC now owns 2,213,052 shares of the biotechnology company's stock valued at $23,414,000 after purchasing an additional 368,379 shares during the last quarter. Orbimed Advisors LLC grew its holdings in Aeglea Bio Therapeutics by 26.9% during the 2nd quarter. Orbimed Advisors LLC now owns 1,865,524 shares of the biotechnology company's stock valued at $19,737,000 after purchasing an additional 396,000 shares during the last quarter. Jennison Associates LLC grew its holdings in Aeglea Bio Therapeutics by 1.4% during the 2nd quarter. Jennison Associates LLC now owns 1,525,447 shares of the biotechnology company's stock valued at $16,139,000 after purchasing an additional 20,349 shares during the last quarter. Baker BROS. Advisors LP grew its holdings in Aeglea Bio Therapeutics by 22.0% during the 2nd quarter. Baker BROS. Advisors LP now owns 1,387,872 shares of the biotechnology company's stock valued at $14,684,000 after purchasing an additional 250,000 shares during the last quarter. Finally, BlackRock Inc. grew its holdings in Aeglea Bio Therapeutics by 3,257.3% during the 2nd quarter. BlackRock Inc. now owns 822,505 shares of the biotechnology company's stock valued at $8,703,000 after purchasing an additional 798,006 shares during the last quarter. Institutional investors own 39.46% of the company's stock.
About Aeglea Bio Therapeutics
Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.
Get a free copy of the Zacks research report on Aeglea Bio Therapeutics (AGLE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter 